Radium-223-Dichloride (Ra-223) is an alpha-emitter, used to treat bonemetastases. Patients with highmetastatic burden and/or with increased trabecular bone uptake could present a higher incidence of hematologic toxicity. We hypothesized that these two factors are predictors of bone marrow failure. Material and Methods. A computer algorithm discriminated between trabecular bone (B-Vol) and tumor metastases (M-Vol) within pretherapeutic whole-body skeletal SPECT/CT (N = 47). The program calculated the metastatic invasion percent (INV%) as the M-Vol/(M-Vol+B-Vol) ratio and extracted the B-Vol mean counts. B-Vol counts were correlated to % drop of hemoglobin (Hb), leukocytes (WBC), and platelets (PLT) after 3/6 Ra-223 cycles. Patient-specific and computational-derived parameters were tested as predictors of hematologic toxicity withMANOVA. Results. B-Vol counts correlated with drop of Hb (R = 0,65, p < 0.01) and PLT (R = 0,45, p < 0.01). Appendicular B-Vol counts showed a better correlation (R < 0.05, p < 0.01, and p < 0.001 for Hb, WBC, and PLT, resp.). INV% directly correlated with B-Vol counts (R = 0.68, p < 0.001). At MANOVA, grade III/ IV toxicity was predicted by INV% (p < 0.01), by long-bone invasion (p < 0.005), and by B-Vol counts (p < 0.05). Conclusions. In patients with significant bone tumor burden, degree of bone invasion and trabecular bone uptake are predictors of subsequent bone marrow failure.

Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients

Fiz, Francesco;Campi, Cristina;Piana, Michele;Sambuceti, Gianmario;
2017

Abstract

Radium-223-Dichloride (Ra-223) is an alpha-emitter, used to treat bonemetastases. Patients with highmetastatic burden and/or with increased trabecular bone uptake could present a higher incidence of hematologic toxicity. We hypothesized that these two factors are predictors of bone marrow failure. Material and Methods. A computer algorithm discriminated between trabecular bone (B-Vol) and tumor metastases (M-Vol) within pretherapeutic whole-body skeletal SPECT/CT (N = 47). The program calculated the metastatic invasion percent (INV%) as the M-Vol/(M-Vol+B-Vol) ratio and extracted the B-Vol mean counts. B-Vol counts were correlated to % drop of hemoglobin (Hb), leukocytes (WBC), and platelets (PLT) after 3/6 Ra-223 cycles. Patient-specific and computational-derived parameters were tested as predictors of hematologic toxicity withMANOVA. Results. B-Vol counts correlated with drop of Hb (R = 0,65, p < 0.01) and PLT (R = 0,45, p < 0.01). Appendicular B-Vol counts showed a better correlation (R < 0.05, p < 0.01, and p < 0.001 for Hb, WBC, and PLT, resp.). INV% directly correlated with B-Vol counts (R = 0.68, p < 0.001). At MANOVA, grade III/ IV toxicity was predicted by INV% (p < 0.01), by long-bone invasion (p < 0.005), and by B-Vol counts (p < 0.05). Conclusions. In patients with significant bone tumor burden, degree of bone invasion and trabecular bone uptake are predictors of subsequent bone marrow failure.
File in questo prodotto:
File Dimensione Formato  
11567-891701.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Documento in versione editoriale
Dimensione 1.9 MB
Formato Adobe PDF
1.9 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/891701
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact